

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| | |
|--------------------------|---------------------|
| OMB APPROVAL | |
| OMB Number: | 3235-0287 |
| Estimated average burden | hours per response: |
| | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | |
|---|--|---|
| 1. Name and Address of Reporting Person* <u>SEIDENBERG BETH C</u> (Last) (First) (Middle) C/O VERA THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 120 (Street) BRISBANE CA 94005 (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>Vera Therapeutics, Inc. [VERA]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below) |
| | 3. Date of Earliest Transaction (Month/Day/Year) 02/03/2023 | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Class A Common Stock | 02/03/2023 | | P | | 46,163 ⁽¹⁾ | A | \$7.24 ⁽²⁾ | 1,389,315 | I | See footnote ⁽³⁾ |
| Class A Common Stock | 02/06/2023 | | P | | 131,602 ⁽⁴⁾ | A | \$7.03 ⁽⁵⁾ | 1,520,917 | I | See footnote ⁽⁶⁾ |
| Class A Common Stock | 02/07/2023 | | P | | 87,956 ⁽⁷⁾ | A | \$7.08 ⁽⁸⁾ | 1,608,873 | I | See footnote ⁽⁹⁾ |
| Class A Common Stock | 02/08/2023 | | P | | 45,357 ⁽¹⁰⁾ | A | \$7.22 ⁽¹¹⁾ | 1,654,230 | I | See footnote ⁽¹²⁾ |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|--|-----|--|-----------------|---|--|--|---|--|
| | | | | | (A) | (D) | Date Exercisable | Expiration Date | | | | | |
| | | | | | Code | V | | | Title | Amount or Number of Shares | | | |

Explanation of Responses:

- The shares were purchased as follows: 44,635 by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 1,528 by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein.
- Represents weighted average purchase price. The shares were purchased at prices ranging from \$7.21 to \$7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- Consists of 1,343,330 shares of Class A Common Stock held by KPCB XVI and 45,985 shares of Class A Common Stock held by XVI Founders.
- The shares were purchased as follows: 127,246 by KPCB XVI and 4,356 by XVI Founders.
- Represents weighted average purchase price. The shares were purchased at prices ranging from \$6.86 to \$7.24. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- Consists of 1,470,576 shares of Class A Common Stock held by KPCB XVI and 50,341 shares of Class A Common Stock held by XVI Founders.
- The shares were purchased as follows: 85,045 by KPCB XVI and 2,911 by XVI Founders.
- Represents weighted average purchase price. The shares were purchased at prices ranging from \$6.97 to \$7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- Consists of 1,555,621 shares of Class A Common Stock held by KPCB XVI and 53,252 shares of Class A Common Stock held by XVI Founders.
- The shares were purchased as follows: 43,856 by KPCB XVI and 1,501 by XVI Founders.
- Represents weighted average purchase price. The shares were purchased at prices ranging from \$7.06 to \$7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- Consists of 1,599,477 shares of Class A Common Stock held by KPCB XVI and 54,753 shares of Class A Common Stock held by XVI Founders.

Remarks:

/s/ Joseph R. Young, Attorney-in-Fact 02/09/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.